SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics ...
BioAtla and GATC Health announce $40 million SPV transaction to advance ozuriftamab vedotin into a registrational trial for 2L+ OPSCC: San Diego Saturday, January 3, 2026, 18:00 H ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback